Clinical trials: Covid
Covid19
ACTIV-6: COVID-19 Study of Repurposed Medications
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
- Trial name
- NCT04885530
- Testing
- Ivermectin, Fluvoxamine, Fluticasone
- Where
- 110 sites in United States
- Volunteers
- 10,956 people
- Sponsor
- Susanna Naggie, MD
SARS CoV 2 Infection
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.
- Trial name
- NCT05172050
- Testing
- Raloxifene
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 61 people
- Sponsor
- Dompé Farmaceutici S.p.A
Severe Acute Respiratory Syndrome, Ventilation Pneumonitis
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.
- Trial name
- IDEA (NCT04425863)
- Testing
- Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets, Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets, Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.
- Where
- Argentina
- Volunteers
- 167 people
- Sponsor
- Eurnekian Public Hospital
COVID-19
Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19
The HCW Prophylaxis (HCWP) Study, single, open and off label intervention study. Up to 350 participants will be assigned to group that takes HCQ or group that opts to not take study medication.
- Trial name
- NCT04435808
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
COVID-19 Testing
COVID-19 Antibody and Reinfection Study
The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to: 1.
- Trial name
- NCT05365750
- Where
- United States
- Volunteers
- 4,235 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Solid Tumor, Sars-CoV2
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of…
- Conditions
- Solid Tumor, Sars-CoV2, Hematological Malignancy
- Trial name
- NCT04347226
- Testing
- BMS-986253
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Columbia University
COVID-19
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.
- Trial name
- NCT04395391
- Testing
- SARS-CoV-2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
COVID-19, Lung Infection
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or…
- Trial name
- NCT04467840
- Testing
- Opaganib
- Where
- 57 sites in United States, Brazil and 8 more
- Volunteers
- 475 people
- Sponsor
- RedHill Biopharma Limited
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Covid19
Enriched Heparin Anti COVID-19 Trial
Coronavirus 19 (COVID-19) is a viral respiratory disease that was identified in December 2019 after the first cases in China, spreading rapidly until reaching pandemic status, causing the collapse of numerous health systems and…
- Trial name
- EnHanCed (NCT04743011)
- Testing
- Heparin sodium
- Where
- 2 sites in Brazil
- Volunteers
- 27 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Acute Respiratory Distress Syndrome, COVID-19 Pneumonia
Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS
A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm.
- Trial name
- NCT04615429
- Testing
- Mesenchymal stromal cells
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cristina Avendaño Solá
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronavirus Disease 2019 (COVID-19)
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC)…
- Trial name
- NCT04409509
- Testing
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
- Where
- 14 sites in United States
- Volunteers
- 124 people
- Sponsor
- CSL Behring
Viral Pneumonia
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection.
- Trial name
- INVENT (NCT06999603)
- Testing
- SNG001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Synairgen Research Ltd.
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
COVID-19
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety…
- Trial name
- NCT04992273
- Testing
- casirivimab+imdevimab
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Regeneron Pharmaceuticals
Critical Confirmed Coronavirus Disease (COVID)-19
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.
- Trial name
- NCT04380961
- Testing
- Sirukumab, Standard of Care (SOC)
- Where
- 16 sites in United States
- Volunteers
- 212 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
COVID 19, ARDS
Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients
This study will establish the safety and efficacy of using stellate ganglion blocks in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 disease.
- Trial name
- NCT04445337
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Nebraska
Coronavirus, Convalescence
Convalescent Plasma to Stem Coronavirus (CSSC-001)
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
- Trial name
- CSSC-001 (NCT04323800)
- Testing
- Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
- Where
- 25 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.